NCT00092495View on ClinicalTrials.gov

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

PHASE3CompletedINTERVENTIONAL
Enrollment

3,055

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

September 30, 2004

Study Completion Date

February 28, 2009

Conditions
Cervical CancerGenital Warts
Interventions
BIOLOGICAL

V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine

qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092495 - Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) | Biotech Hunter | Biotech Hunter